Financing channel feed – Endpoints News

Financing channel feed

Tiny player picks up $30M to go after CAR-T's biggest challenges

4 years ago

ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer's and a lot more

4 years ago

RA Capital kicks off third VC fund as Peter Kolchinsky and Rajeev Shah bank $880M

4 years ago

UBS wants to make an 'impact' with a new fund, shelling out $650M to join MPM

4 years ago

NFX targets seed and pre-seed companies with latest $450M round

4 years ago

New small molecule player with roots in David Liu's lab collects another $78M to fuel search for exosites

4 years ago

IPOs get back into gear with filings from LianBio and Xilio, and Cormorant's SPAC has a deal

4 years ago

Closing out a quiet week on Wall Street, a new SPAC prices its public debut and begins the search for a biotech partner

4 years ago

After years of running trials for other drugmakers, TrialSpark is building its own pipeline

4 years ago

The cash won't stop for Exscientia as it makes a $300M+ Nasdaq debut

4 years ago

A newly private Novartis partner bags a megaround on its first go to turbocharge CAR-T, cell therapy pipeline

4 years ago

The $165M immunology startup Sheila Gujrathi bet on after Receptos, Gossamer is shooting for an IPO

4 years ago

Amicus spins out gene therapy unit in SPAC deal as it pivots efforts toward Pompe disease program

4 years ago

Drugging RNA was once considered impossible. Now Big Pharma can't get enough of it

4 years ago

On a journey to drastically speed up cell therapy manufacturing, Kytopen lands $30M Series A

4 years ago

Looking to rewrite the rules of drug licensing, startup Anji is on the hunt for 'dynamic equity' joint ventures

4 years ago

A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects

4 years ago

Trevor Bedford, Cigall Kadoch among this year's incoming HHMI investigators

4 years ago

Looking to make donor cells obsolete, an ex-Harvard researcher gets off-the-shelf stem cell biotech off the ground

4 years ago

Eli Lilly gets behind the latest approach to solving gene therapy's delivery problem

4 years ago

Hexagon Bio raises $61M to continue efforts to turn fungi into drugs

4 years ago

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever

4 years ago

Time for round 2: Illumina-backed VC snags $325M for its next fund

4 years ago

Continuity and diversity: Rafaèle Tordjman's women-led VC firm tops out first fund at $630M

4 years ago

First page Previous page 65 66 676869 70 71 Next page Last page